Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s S...
December 13 2018 - 8:35AM
Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today
that the United States Patent and Trademark Office has given notice
that it will allow a patent covering the concomitant use of Korlym®
and drugs from the class of medications known as strong CYP3A
inhibitors to treat patients with hypercortisolism (Cushing’s
syndrome). The patent will expire in 2037.
“This patent covers an important finding of our
research – that with proper dose modulation, Korlym can safely be
administered in combination with medications that are strong CYP3A
inhibitors,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive
Officer. “Strong CYP3A inhibitors include antiviral, antibiotic,
antifungal and antidepressant medications from which many patients
taking Korlym could benefit. Korlym’s label instructs doctors
how to do this safely.”
Upon issuance, Corcept plans to list the patent,
entitled “Concomitant Administration of Glucocorticoid Receptor
Modulators and CYP3A Inhibitors” (U.S. Pat. App. 15/627,359), in
the FDA’s Approved Drug Products with Therapeutic Equivalence
Evaluations (the “Orange Book”). Korlym is currently covered
by five patents listed in the Orange Book.
About Cushing’s Syndrome
Hypercortisolism, often referred to as Cushing’s
syndrome, is caused by excessive activity of the stress hormone
cortisol. Endogenous Cushing’s syndrome is an orphan disease that
most often affects adults aged 20-50. In the United States, an
estimated 20,000 patients have Cushing’s syndrome, with about 3,000
new patients being diagnosed each year. Symptoms vary, but most
people experience one or more of the following manifestations: high
blood sugar, diabetes, high blood pressure, upper-body obesity,
rounded face, increased fat around the neck, thinning arms and
legs, severe fatigue and weak muscles. Irritability, anxiety,
cognitive disturbances and depression are also common. Cushing’s
syndrome can affect every organ system in the body and can be
lethal if not treated effectively.
About Corcept Therapeutics
Incorporated
Corcept Therapeutics is engaged in the
discovery, development and commercialization of drugs to treat
severe metabolic, oncologic and psychiatric disorders by modulating
the effects of the stress hormone cortisol. Corcept’s first
approved product, Korlym, inhibits the effects of excess cortisol
in patients with hypercortisolism by modulating activity at the
glucocorticoid receptor, one of the two receptors to which cortisol
binds. Korlym was the first FDA-approved treatment for patients
with Cushing’s syndrome and the FDA has designated it as an Orphan
Drug for that indication. Corcept has created a large portfolio of
proprietary compounds that modulate the effects of cortisol but not
progesterone. The company owns extensive United States and foreign
intellectual property covering the use of cortisol modulators in
the treatment of a wide variety of serious disorders. The company
also holds composition of matter patents covering its selective
cortisol modulators. Corcept is conducting a Phase 3 trial of its
lead proprietary molecule, relacorilant, to treat patients with
Cushing’s syndrome.
Forward-Looking Statements
Statements in this press release, other than
statements of historical fact, are forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, are based on our current plans and
expectations and are subject to risks and uncertainties that might
cause actual results to differ materially from those such
statements express or imply. These risks and uncertainties
include, but are not limited to, our ability to generate sufficient
revenue to fund our commercial operations and development programs;
the protections afforded by patents and our other intellectual
property; and risks related to the development of relacorilant,
including regulatory approvals, mandates, oversight and other
requirements. These and other risks are set forth in our
Securities and Exchange Commission (“SEC”) filings, which are
available at our website and the SEC’s website. In this press
release, forward looking statements include those regarding patent
coverage for Korlym, the potential for patients receiving Korlym to
benefit from the concomitant administration of one or more strong
CYP3A inhibitors and our plans to list the newly allowed patent in
the Orange Book. We disclaim any intention or duty to update
forward-looking statements made in this press release.
CONTACT:Charles RobbChief Financial
OfficerCorcept
Therapeutics650-688-8783crobb@corcept.comwww.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2023 to Apr 2024